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Abstract
Oncogenic receptor tyrosine kinase (RTK) signaling through the Ras-Raf-Mek-Erk (Ras-MAPK) pathway is implicated
in a wide array of carcinomas, including those of the breast. The cyclin-dependent kinases (CDKs) are implicated in
regulating proliferative and survival signaling downstream of this pathway. Here, we show that CDK inhibitors
exhibit an order of magnitude greater cytotoxic potency than a suite of inhibitors targeting RTK and Ras-MAPK sig-
naling in cell lines representative of clinically recognized breast cancer (BC) subtypes. Drug combination studies
show that the pan-CDK inhibitor, flavopiridol (FPD), synergistically potentiated cytotoxicity induced by the Raf inhib-
itor, sorafenib (SFN). This synergy was most pronounced at sub-EC50 SFN concentrations in MDA-MB-231 (KRAS-
G13D and BRAF-G464V mutations), MDA-MB-468 [epidermal growth factor receptor (EGFR) overexpression], and
SKBR3 [ErbB2/EGFR2 (HER-2) overexpression] cells but not in hormone-dependent MCF-7 and T47D cells. Poten-
tiation of SFN cytotoxicity by FPD correlated with enhanced apoptosis, suppression of retinoblastoma (Rb) signal-
ing, and reduced Mcl-1 expression. SFN and FPD were also tested in an MDA-MB-231 mammary fat pad
engraftment model of tumorigenesis. Mice treated with both drugs exhibited reduced primary tumor growth rates
and metastatic tumor load in the lungs compared to treatment with either drug alone, and this correlated with greater
reductions in Rb signaling and Mcl-1 expression in resected tumors. These findings support the development of CDK
and Raf co-targeting strategies in EGFR/HER-2–overexpressing or RAS/RAF mutant BCs.
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Introduction
Chemotherapy-related morbidity and drug-resistant recurrence have
prompted intensive investigation of the molecular mechanisms under-
lying carcinogenesis. These efforts have led to the development of
monotargeted therapies such as trastuzumab, a humanized monoclonal
antibody, and lapatinib, a receptor tyrosine kinase (RTK) inhibitor to
target ErbB2/epidermal growth factor receptor 2 (HER-2)–positive
breast cancer (BC) [1–3]. Notwithstanding these early successes, the
use of these monotargeted therapies alongside chemotherapy has been
fraught with clinical dilemmas including intertumor and intratumor
heterogeneity, intrinsic and adaptive drug resistance, and off-target
toxicity [4,5].
The epidermal growth factor receptor (EGFR/HER-1/ErbB1) and
HER-2 have been implicated in BC pathogenesis. HER-2 is over-
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expressed in approximately 20% of BC cases and is associated with
poor prognosis [3], while EGFR has been shown to be overexpressed
in 35% of recurrent cases [6]. Expression of EGFR in BC has been
inversely correlated with relapse-free survival and is associated with a lack
of response to hormone therapy [7]. Both EGFR and HER-2 regulate
downstream tumor cell proliferation and survival through the Ras-Raf-
Mek-Erk (Ras-MAPK) and phosphatidylinositol-3-kinase (PI3K)-Akt
pathways. Mutations in RAS, RAF, PI3K, and PTEN are strongly asso-
ciated with tumor initiation and progression and have been identified
with high frequency in various malignancies including BC [8,9].
The Ras-MAPK pathway is a common downstream pathway for
numerous RTK systems and is a major focal point in cancer therapy
development [8]. Upstream RTK overexpression or activating muta-
tions in RAS and RAF are strongly implicated in driving oncogenesis
through constitutive activation of the MAPK pathway. The Ras-Raf
oncogenic axis transduces survival and proliferative signals through
both Mek-Erk–dependent and Mek-Erk–independent Raf signaling
pathways [10]. Hence, Raf is a regulatory nexus in RTK-mediated
proliferative and survival signaling and its inhibition has become a
central strategy in the development of treatments for melanoma,
kidney, liver, and breast carcinoma [11,12].
In addition to Raf, cyclin-dependent kinases (CDKs) have also
emerged as attractive targets for cancer intervention [13]. CDKs are
an important regulatory component of the retinoblastoma (Rb)–E2F
signaling axis. The Rb-E2F axis can be activated by Mek-Erk–
dependent or Mek-Erk–independent Raf signaling [10]. Activation
through Mek-Erk–dependent signaling occurs through cyclin D1
induction and subsequent assembly of cyclin D1–CDK4/CDK6 and
–CDK2 complexes. These complexes promote Rb phosphorylation,
resulting in Rb-E2F dissociation and G1-S cell cycle transition through
E2F-dependent transcriptional programs. Perturbation of the Rb-E2F
signaling axis commonly occurs in cancer through gene amplifications,
deletions, and functional alterations of its key signaling regulators.
Perturbations frequently involve loss of Rb, cyclin D1 amplification,
or CDK4 overexpression; these alterations have been associated with
poor prognosis in many cancers including HER-2–positive BC [14–16].
Sorafenib (SFN; BAY 43-9006; Nexavar) is a broad-spectrum
multi-kinase small molecule inhibitor. In vitro recombinant kinase
assays have shown that SFN potently inhibits both the CRAF
(Raf-1) and BRAF isoforms, including the highly oncogenic
V600E variant [17]. SFN disrupts Ras-MAPK signaling in cell-based
assays and this has been correlated with antitumor effects in colon,
kidney, lung, and breast xenograft models [11,17]. SFN has been
approved for treatment in advanced renal cell and hepatocellular
carcinoma [18,19]. Most recently, SFN has been shown to increase
progression-free survival in HER-2–negative metastatic BC when
used in combination with capecitabine [12].
Flavopiridol (FPD; HMR-1275; Alvocidib) is a small molecule
semisynthetic alkaloid that competes with ATP to inhibit CDK-1,
-2, -4, -6, -7, and -9 [20]. This pan-CDK inhibitor exhibited con-
siderable promise in phase I and II trials, showing partial or complete
response as well as disease stabilization in advanced malignancies
including ovarian, pancreas, gastric, and colon cancers and BC [21,22].
CDK inhibitors with increased selectivity (i.e., AZD5438 and
PD0332991) have also been developed, which inhibit Rb-associated
tumorigenesis in various preclinical human tumor xenograft models
[23,24]. Cell-based studies have shown that FPD and other CDK
inhibitors induce cell cycle arrests in G1-S or G2-M that are associated
with antiproliferative and cytotoxic effects. CDK-induced cytotoxicity
may underlie systemic toxicity issues of FPD and other CDK inhibitors
in clinical trials [24–26].
In this study, we tested the cytotoxic potency and efficacy of a
panel of RTK pathway (RTK-P) and CDK inhibitors across cell line
models representative of clinically recognized BC subtypes. CDK
inhibitors were found to exhibit significantly greater cytotoxic potency
than RTK-P inhibitors in all tested lines. FPD most strongly poten-
tiated cytotoxicity induced by SFN in vitro and in vivo. Potentiation
occurred in cell lines harboring constitutive Ras-MAPK activation
associated with EGFR/HER-2 overexpression or KRAS-BRAF muta-
tions. Our data suggest that co-targeting CDKs and the Ras-MAPK
pathway with FPD and SFN, respectively, enhances SFN killing effi-
cacy at low doses. These data suggest a potential role for FPD in poten-
tiating SFN therapeutic efficacy in the clinic.
Materials and Methods
Cell Lines and Reagents
MDA-MB-468, SK-BR3, MCF-7, and T47D BC lines were
obtained from American Type Culture Collection (Manassas, VA).
MDA-MB-231 cells were provided by Dr Peter Siegel (McGill Uni-
versity, Montreal, Quebec). SFN, FPD, lapatinib, and erlotinib were
obtained from Toronto Research Chemicals (Toronto, Ontario).
Fascaplysin, U0126, LY294002, and U73122 were purchased from
Sigma-Aldrich (Oakville, Ontario). AZD5438 and PD0332991 were
purchased from Selleckchem (Houston, TX). SFN and FPD used for
xenograft studies were acquired from UHN Shanghai R&D Co
(Shanghai, China).
Cytotoxicity Assay
Cells (2 × 104 per well in 96-well plates) were treated with increas-
ing concentrations of the indicated drugs for 72 hours in standard cul-
ture media. For drug combination experiments, cells were treated
with varying concentrations of a primary drug in the presence of a
fixed concentration (0.2 μM) of a secondary drug. Cell viability was
assessed by metabolic activity using 3-(4,5-dimethylthiazol-2-yl)-2,
5-diphenyltetrazolium bromide assay (Sigma-Aldrich). Drug interac-
tions were analyzed using CALCUSYN software by Chou and Talalay
(Biosoft, Ferguson, MO) that quantitatively assesses the nature of drug
interactions using multiple drug effect/combination index (MDE-CI)
isobologram analysis. This analysis calculates a CI for drug interactions.
CI values less than 0.9 indicate synergy; CI values between 0.9 and
1.1 indicate additivity, and CI values greater than 1.1 indicate antag-
onism [27]. F a reflects the proportion of cells killed or no longer viable
as a result of drug treatment and was calculated using the following
equation: F a = (A570 control − A570 treated)/A570 control [2,28].
Apoptosis Assay
Cells (1 × 106 cell per well in a six-well plate) were treated with the
indicated drugs for 24 hours. After treatment, cells were incubated
(30 minutes, 37°C) with propidium iodide (PI) and the annexin
XII–based phosphatidylserine fluorescent sensor pSIVA-IANBD
(Imgenex, San Diego, CA). Annexin XII+|PI− cells representative of
apoptotic cells were counted on a Beckman Coulter flow cytometer
(Mississauga, Ontario).
Signaling Experiments
Cells (1 × 107 per 10-cm plate) were treated with SFN or FPD
alone or in combination at the indicated times and concentrations
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in standard culture media. After treatment, cells were lysed in radio-
immunoprecipitation assay buffer supplemented with protease inhib-
itors and clarified by centrifugation (12,000g, 10 minutes). Equal
quantities of protein were separated by sodium dodecyl sulfate–
polyacrylamide gel electrophoresis and assayed by immunoblot (IB)
analysis using the indicated antibodies. All antibodies were purchased
from Cell Signaling Technology (Beverly, MA).
Preclinical In Vivo Drug Testing
Logarithmically growing MDA-MB-231 cells were resuspended in
1:1 phosphate-buffered saline (PBS)/Matrigel (Sigma-Aldrich) solu-
tion. Fifty microliters (2 × 106 cells) of the solution was injected into
the right inguinal mammary gland of BalbC-RAG2−/−|IL2Rγc−/− mice
(kindly provided by Dr M. Ito, Central Institute of Experimental
Animals, Kawasaki, Japan). SFN was dissolved in H2O containing
12.5% Cremophor EL (Sigma-Aldrich) and 12.5% ethanol and
administered by oral gavage [29]. FPD was dissolved in PBS and
administered by intraperitoneal injection (i.p.). Mice were randomized
into four cohorts (six/cohort). The control cohort received PBS (i.p.)
and treatment cohorts received either SFN (30 mg/kg, oral gavage),
FPD (3 mg/kg, i.p.), or SFN-FPD (30 and 3 mg/kg, respectively)
[17,30]. Treatment was initiated 7 days post-engraftment and contin-
ued every 2 days for 28 days. Tumor sizes were measured every 2 days
using calipers. After 35 days, tumors were resected, bisected, and either
lysed in radioimmunoprecipitation assay buffer for IB analysis or
formalin-fixed and paraffin-embedded (FFPE) for histologic analysis.
IBs were quantified using ImageJ software [31].
Fluorescence In Situ Hybridization Analysis
Fluorescence in situ hybridization (FISH)–based identification of
lung-metastasized xenograftedMDA-MB-231 cells was performed using
the human Cep17 SpectrumGreen Probe (D17Z1, 17p11.1-q11.1
Alpha Satellite DNA; Abbott Molecular, Markham, Ontario) and
counterstained for nuclei with 4′,6-diamidino-2-phenylindole (DAPI).
Ten randomly selected regions representative of general whole lung
morphology from each lung section were independently assessed for total
FISH Cep17 signal and nuclei number using ePATHOLOGY
IMAGESCOPE (Aperio, Vista, CA) and IMAGEPRO software (Media
Cybernetics, Rockville,MD). The ratio ofCep17 probe signals to DAPI-
stained nuclei was calculated to determine the relative burden of MDA-
MB-231 cells metastasized in murine lungs from each treatment cohort.
Results
CDK Inhibitors Are Significantly More Cytotoxic than
RTK-P Inhibitors
The kill efficacy (K Eff; maximal number of cells killed) and cyto-
toxic potency (EC50; dose required to induce half-maximal cell kill)
of a panel of RTK-P inhibitors targeting EGFR/HER-2, Raf, Mek,
PI3K, and phospholipase C (PLC) were compared to a panel of CDK
inhibitors (Table 1) in five BC cell lines. In metastatic MDA-MB-231
cells, the K Eff of CDK and RTK-P inhibitors spanned similar ranges
(21-100%; Table 2). In contrast, the EC50 ranges for the CDK inhibi-
tor panel were markedly lower than the EC50 ranges for the RTK-P panel
(0.2-0.7 μM vs 8.6-36.4 μM, respectively; Table 2). These differences
were clearly indicated by the cytotoxicity profiles of the CDK inhibitors,
which clustered distinctly left of RTK-P profiles on the dose axis
(Figure 1A). Subsequent estimation of the average EC50 of the two
inhibitor panels showed that CDK inhibitors induce cell death with
approximately 54-fold more potency than RTK-P inhibitors in MDA-
MB-231 cells (Table 2). To investigate whether this potency enhance-
ment was cell-line specific, EGFR-overexpressing (MDA-MB-468),
HER-2–overexpressing (SKBR3), and hormone-dependent (MCF-7
and T47D) BC cell lines were also tested (Table 3). The K Eff of
CDK and RTK-P inhibitors in these lines spanned ranges comparable
to those in MDA-MB-231 cells. More strikingly however, the CDK
cytotoxicity profiles of these four lines also clustered distinctly left of
the RTK-P profiles on the dose axis (Figure 1, B–E). Taken together,
these results indicate that CDK inhibitors induce cytotoxicity with
significantly greater potency than RTK-P inhibitors in BC lines.
Table 1. CDK Inhibitors.
Targets FPD AZD5483 PD0332991 Fascaplysin
CDK1-CycB 0.027 0.016 >10 >100
CDK2-CycA 0.405 0.045 >10 >50
CDK2-CycE 0.282 0.006 >10 >50
CDK4-CycD1 0.132 0.449 0.011 0.35
CDK4-CycD2 – – – >100
CDK4-CycD3 – – 0.009 >100
CDK6-CycD1 – – – 3.4
CDK6-CycD2 – – 0.015 >50
CDK6-CycD3 0.395 0.021 – –
CDK7-CycH 0.514 0.821 – –
CDK9-CycT 0.011 0.020 – –
Comparison of IC50 (μM) of FPD, AZD5483, PD0332991, and fascaplysin against various
CDK-cyclin complexes [23,47,48]; –, undetermined.
Table 2. Potency and Efficacy of Inhibitor Panels.
Cell Line Drug Panel Potency Range, EC50 (μM) Mean Potency, EC50 (μM) (± SEM) Maximal Kill Efficacy Range, K Eff (%)
MDA-MB-231 Anti-CDK 0.2-0.7 0.43 ± 0.7 23-75
Anti–RTK-P 8.6-36.4 23.4 ± 0.6 21-100
MDA-MB-468 Anti-CDK 0.1-1.1* 0.36 ± 0.5 23-97
Anti–RTK-P 7.7-40.3 16 ± 0.7 44-100
SKBR3 Anti-CDK 0.1-0.6 0.36 ± 0.9 18-100
Anti–RTK-P 3.9-25.7 17.9 ± 0.5 41-100
MCF-7 Anti-CDK 0.2-0.6 0.45 ± 0.8 37-95
Anti–RTK-P 13.3-67.2 29.3 ± 0.5 29-100
T47D Anti-CDK 0.3-0.9 0.66 ± 0.6 37-90
Anti–RTK-P 5.8-61.7 ** 21.9 ± 0.4 43-100
Potency (EC50) and maximal kill efficacy (K Eff ) of each inhibitor panel in BC lines. K Eff and EC50 were estimated by fitting inhibition data to a four-parameter sigmoidal function. In cases where cell kill
did not reach saturation, K Eff was taken to be the value at the highest drug dose tested and this value was used to constrain fitting. EC50 values in these cases would be underestimated. Estimates for
PD0332991 (*) and U0126 (**) were indeterminate.
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FPD and Fascaplysin Potentiate SFN Cytotoxicity in
MDA-MB-231 Cells
The marked increases in potency observed with the CDK inhibitor
panel underscored their potential use as cytotoxicity-enhancing agents
for therapies targeting the Ras-MAPK pathway. This prompted us to
explore potential synergistic cytotoxic effects of CDK inhibitors with
the Raf inhibitor SFN in MDA-MB-231 cells. These cells harbor
oncogenic KRAS and BRAF mutations associated with constitutive
Ras-MAPK signaling (Table 3). When CDK inhibitors were added
at fixed concentrations to varying concentrations of SFN, cytotoxicity
was potentiated in this line (Figure 2, A and B). Potentiation was sub-
stantially more pronounced with FPD and fascaplysin than with either
PD0332991 or AZD5438 at SFNconcentrations below its EC50 (≤5 μM;
compare Figure 2, A and B to C and D). The fraction of cells killed by
0.2 μMof either FPD or fascaplysin alone was significantly less than that
observed in combination with SFN, indicating that these combinations
Figure 1. Comparison of cytotoxicity induced by CDK and RTK-P inhibitors. (A) MDA-MB-231, (B) MDA-MB-468, (C) SKBR3, (D) MCF-7,
and (E) T47D cells were treated with increasing concentrations of the indicated inhibitors. Cell viability was assayed after 72 hours. The
fraction of cells killed (Fa ± SEM) by treatment with a panel of CDK inhibitors (solid markers) and RTK-P inhibitors (open markers) are
shown. The RTK-P inhibitors U0126, erlotinib, lapatinib, SFN, U73122, and LY294002 were used to inhibit Mek, EGFR, EGFR/HER-2, Raf,
PLC, and PI3K, respectively. Dose-effect profiles are representative of two to three independent experiments.
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can potentiate cytotoxicity to levels greater than the summed effects of
individual drugs (compare shaded line with drug response curves in Fig-
ure 2,A andB).We further assessed the nature of these drug interactions
using MDE-CI analysis (see Materials and Methods section) [2,27].
This analysis yielded CI values indicative of synergy (<0.9) and addi-
tivity (0.9-1.1) at the higher range of tested ratio combinations (Figure 2,
A and B, lower panels, black and gray bars, respectively). Synergy was
associated with FPD/SFN and fascaplysin/SFN combination ratios
ranging from 1:6 to 1:25. MDE-CI analysis did not indicate synergistic
or additive interactions between PD0332991 or AZD5438 and SFN
(Figure 2, C and D, lower panels). Taken together, these results show
that specific ratio combinations of SFN and the CDK inhibitor FPD
or fascaplysin synergistically potentiate cytotoxicity in MDA-MB-
231 cells.
FPD Potentiates SFN Cytotoxicity in
MDA-MB-468 and SKBR3 Cells
We extended our analyses to MDA-MB-468, SKBR3, MCF-7, and
T47D cells and focused efforts on FPD, which has undergone extensive
testing in clinical trials [22,25,26]. Interestingly, FPD failed to poten-
tiate cytotoxicity in hormone-dependent MCF-7 and T47D cells
(Figure 3, A and B, upper panels). Consistent with this, synergistic
interactions between these drugs were not detected in these lines (Fig-
ure 3, A and B, lower panels). We next tested for potentiating inter-
actions between these drugs in MDA-MB-468 and SKBR3 cells,
which harbor constitutive Ras-MAPK signaling associated with EGFR
and HER-2 overexpression, respectively (Table 3). Exploration of drug
ratio combinations in MDA-MB-468 cells indicated synergy between
FPD and SFN ratios ranging from 1:6 to 1:25; these interactions
became additive as ratios decreased (Figure 3C ). Synergy was only
indicated at the highest FPD to SFN ratio tested in SKBR3 cells
(1:6; Figure 3D). As observed inMDA-MB-231 cells, synergy was only
evident at SFN concentrations below the EC50 of the tested lines.
Together with the observations made in MDA-MB-231 cells, these
data suggest that specific ratio combinations of FPD and SFN syner-
gistically potentiate cytotoxicity in BC cells harboring constitutive Ras-
MAPK signaling.
FPD Potentiates SFN-Induced Apoptosis in MDA-MB-231
and MDA-MB-468 Cells
Combination studies showed that FPD-SFN used at a ratio of
1:25 induced cytotoxic synergy in MDA-MB-231 and MDA-MB-
468 cells (Figures 2A and 3C ). Focusing on these two lines, we tested
whether the same FPD-SFN combination ratio could also potentiate
apoptosis. Annexin XII–based phosphatidylserine-binding assays
showed that FPD and SFN alone induced levels of apoptosis that
were significantly less than that induced by FPD-SFN combinations
used at 1:25 ratios in MDA-MB-231 (Figure 4A) and MDA-MB-468
(Figure 4B) cells. The enhancement produced by the combination
was greater than theoretically expected additive effects, suggesting that
these drugs synergistically interact to induce programmed cell death in
both lines (Figure 4, A and B). These data suggest that a 1:25 ratio of
FPD-SFN supra-additively potentiates apoptosis in MDA-MB-231
and MDA-MB-468 cells.
FPD and SFN Cooperatively Dysregulate Rb and Mcl-1
The Ras-MAPK and Rb-E2F signaling axes play critical roles in
cancer cell proliferation and survival [8,14]. Assessment of Ras-
MAPK activity using an active-state antibody against Erk (pErk)
showed that SFN alone strongly suppressed pErk in MDA-MB-231
cells for up to 2 hours before undergoing periodic oscillations in
activity at 4 and 24 hours (Figure 5A). This periodic Erk signal recov-
ery could represent normal oscillatory behavior of Erk activity recently
described in asynchronously growing cells [32]. Expectedly, FPD did
not affect pErk signaling in this line (Figure 5B), and consistent with
this, it did not significantly alter Erk inhibition when added to SFN
(Figure 5C ). In MDA-MB-468 cells, FPD and SFN alone or in com-
bination failed to inhibit pErk signaling (Figure 5, D–F ). Signaling
through the Rb-E2F pathway was also assessed by Rb phosphorylation
(pRb) at S807/811 [33]. pRb was partially suppressed by SFN and only
intermittently by FPD in MDA-MB-231 cells (Figure 5, A and B).
However, when FPD was combined with SFN, maximal suppression
was observed for the full length of the treatment period (Figure 5C ). In
contrast, FPD or SFN alone or in combination failed to suppress pRb
inMDA-MB-468 cells (Figure 5,D–F). Lastly, SFN and FPD in com-
bination reduced expression ofMcl-1 to greater extents than either drug
Table 3. Human Breast Cancer Cell Line Models [55,56].
Cell Line Clinical Markers Mutational Status* Tumor Type Tumor Classification
MDA-MB-231 TN–Claudin low TP53 Adenocarcinoma† Basal B
KRAS‡
BRAF§
CDKN2A
MDA-MB-468 EGFR positive¶ PTEN Adenocarcinoma† Basal A
TP53
MADH4
RB1
SKBR3 HER-2 positive# (NA)** Adenocarcinoma† Luminal
T47D ER/PR positive PIK3CA Invasive ductal carcinoma† Luminal
TP53
MCF-7 ER/PR positive PIK3CA Invasive ductal carcinoma† Luminal
CDKN2A
*Cancer Genome Project, Sanger Institute (http://www.sanger.ac.uk/genetics/CGP/CellLines).
†Isolated from metastatic pleural effusion.
‡KRAS G13D mutation.
§BRAF G464V mutation.
¶EGFR overexpression (gene amplification).
#HER-2 overexpression (gene amplification).
**Not available.
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alone in bothMDA-MB-231 andMDA-MB-468 cells (Figure 5, A–F ).
These data suggest that pRb suppression and reduced Mcl-1 expression
underlie enhanced cytotoxicity associated with FPD-SFN combinations.
Maximal Tumor Growth Suppression In Vivo with
FPD and SFN Coadministration
We next tested whether FPD-SFN combinations could potentiate
antitumor activity in vivo. MDA-MB-231 cells were orthotopically
engrafted in mammary fat pads of BalbC-RAG2−/−|IL2Rγc−/− mice.
FPD and SFN alone or in combination at a 1:10 ratio—which falls
within the 1:6 to 1:25 range observed in vitro—was administered to
assess relative effects on antitumor activity. SFN alone significantly
reduced the rate of tumor development relative to control mice
(Figure 6A) [17]. FPD alone also significantly suppressed tumor de-
velopment rates compared to controls, although not to the same ex-
tent observed with SFN. FPD and SFN in combination, however,
Figure 2. Potentiation of SFN-induced cytotoxicity by a panel of CDK inhibitors in MDA-MB-231 cells. (A–D, upper panels) The fraction of
cells killed (Fa ± SEM) by SFN in the presence of DMSO (vehicle) or a fixed concentration (0.2 μM) of FPD (A), fascaplysin (B), PD0332991
(C), and AZD5438 (D). The fraction of cells killed by CDK inhibitors at a fixed concentration of 0.2 μM is shown for comparison [dashed
lines; gray shading (±SEM)]. (A–D; lower panels) MDE-CI analysis of drug interactions in the upper panels. CIs as a function of SFN
concentration are shown. Black, gray, and white bars denote synergistic (CI < 0.9), additive (CI = 0.9-1.1), or antagonistic interactions
(CI > 1.1), respectively. Synergistic ratios and SFN-EC50 are indicated. Data are representative of two to three independent experiments.
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produced the greatest level of tumor growth suppression (Figure 6A).
Importantly, all six mice of each treatment cohort survived with no ad-
verse toxicity reactions of weight loss. Thus, FPD-SFN combinations
associated with enhanced cytotoxicity and apoptosis in vitro also pro-
mote antitumor effects when administered at a similar ratio in vivo.
Cooperative Inhibition of Pulmonary Metastatic Tumor Load
by Combined FPD and SFN Treatment
Whole lungs resected after 35 days of treatment were examined for
histologic evidence of metastases (Figures W1–W3). Pathologic
assessment suggested that metastatic tumor burden in the lung was
Figure 3. Potentiation of SFN-induced cytotoxicity by FPD inMCF-7, T47D,MDA-MB-468, and SKBR3 cells. (A–D, upper panels) The fraction
of cells killed (Fa ± SEM) by SFN in the presence of DMSO (vehicle) or a fixed concentration (0.2 μM) of FPD in MCF-7 (A), T47D (B), MDA-
MB-468 (C), and SKBR3 (D) cells. The fraction of cells killed by CDK inhibitors at a fixed concentration of 0.2 μM is shown for comparison
[dashed lines; gray shading (±SEM)]. (A–D, lower panels) MDE-CI analysis of drug interactions in the upper panels. CIs as a function of SFN
concentration are shown. Black, gray, and white bars denote synergistic (CI < 0.9), additive (CI = 0.9-1.1), or antagonistic interactions (CI >
1.1), respectively. Synergistic ratios and SFN-EC50 are indicated. Data are representative of two to three independent experiments.
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significantly less in the SFN-treated group compared to the FPD- or
control-treated group (Figure W1). FISH analyses quantifying the
ratio of human-specific Cep17 signal to the number of DAPI-stained
nuclei corroborated this pathologic assessment (Figure W2) and fur-
ther verified that the number of metastatic BC cells in the lung was
suppressed by either FPD or SFN treatment alone. The most pro-
nounced suppression, however, was observed with FPD and SFN
co-treatment (Figure 6B), which paralleled the suppressive effects
of this combination on tumor growth at the orthotopic site.
FPD and SFN Combinations Maximally Inhibited Erk, Rb,
and Mcl-1 In Vivo
The molecular mechanisms underlying tumor suppression were
assessed by measuring pErk, pRb, and Mcl-1 expression in resected
tumors (Figure 7A). In comparison to the control cohort, the FPD-
treated group did not show significant differences in pErk inhibition
(Figure 7B), Rb phosphorylation (Figure 7C ), or Mcl-1 expression
(Figure 7D). SFN also failed to suppress Rb phosphorylation and
paradoxically increased pErk and Mcl-1 levels. However, FPD and
SFN in combination affected all three signaling proteins as indicated
by significant reductions in pErk, pRb, and Mcl-1 levels relative to
controls (Figure 7, B–D). These data show that combined FPD and
SFN treatment maximally suppress levels of pErk, pRb, and Mcl-1,
and this correlates with the enhanced antitumor effects produced by
this combination.
Discussion
Overexpression of RTKs or activating mutations residing within
nodes of the Ras-Raf-MAPK and PI3K-Akt pathways are associated
with poor prognosis and have become focal points of targeted ther-
apy strategies. We evaluated the general merit of such strategies in
BC by exploring the cytotoxic effects of a panel of RTK-P inhibitors
targeting EGFR, HER-2, PLC, Raf, Mek, and PI3K in cell lines rep-
resentative of EGFR/HER-2–overexpressing, hormone-dependent,
and triple-negative (TN) BC subtypes. Our findings showed that
the mean cytotoxic potency (EC50) of the RTK-P inhibitor panel
was narrow, ranging from 16 to 29 μM across all lines (Table 2).
In comparison, a panel of four CDK inhibitors with highly varied
substrate specificities exhibited a very tight mean potency range of
0.4 to 0.7 μM across the same five lines (Table 2). These relatively
narrow ranges suggest that improvements in potency achievable
within anti–RTK-P or anti-CDK treatment modalities are limited.
Across these modalities however, we see compelling improvements
Figure 4. Potentiation of SFN-induced apoptosis by FPD. Cells were treated with either DMSO, 0.2 μM FPD, 5 μM SFN, or 1:25 ratio of
FPD-SFN (0.2 μM and 5 μM, respectively) for 24 hours. The percentages (mean ± SEM) of early apoptotic (annexin XII+), non-necrotic (PI−)
MDA-MB-231 (A) and MDA-MB-468 (B) cells detected after drug treatment (gray bars) are shown. The white bar indicates the fraction of
apoptotic cells expected by simple addition of the percentage of apoptotic cells induced by SFN or FPD alone. Significant P values are
indicated (t test; n = 3-4).
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in cytotoxic potential. Our data show that the average EC50 of the
CDK inhibitor panel is well over an order of magnitude less than the
average EC50 of the RTK-P inhibitor panel (0.45 μM vs 21.7 μM,
respectively) reflecting a 48-fold improvement in potency. Perhaps
more compelling is the ubiquity of this improvement across a mor-
phologically and clinically diverse panel of BC lines (Table 3). These
data clearly indicate that CDK targeting is a substantially more potent
alternative to inducing cell death than RTK-P targeting. The reasons
for this are presently unclear but may be due to the fact that CDKs lie
downstream of RTK-P targets and constitute a major regulatory point
of mitogenic and survival signal convergence.
The potency with which CDK inhibitors induce cell death indi-
cates that BC cell survival may be highly sensitive to disruption in
CDK activity. Consistent with this, FPD and fascaplysin strongly
potentiated SFN cytotoxicity in MDA-MB-231 cells (Figure 2).
MDE-CI analysis indicated that FPD or fascaplysin synergistically
interacts with SFN. Focusing on the clinically tested drug FPD,
we also observed synergy with SFN in MDA-MB-468 and SKBR3
cells but not in hormone-dependent MCF-7 and T47D cells (Fig-
ure 3). Cytotoxic synergy in all lines occurred at low (sub-EC50)
SFN concentrations and at FPD-SFN ratios ranging from 1:6 to
1:25. We also observed that cytotoxic synergy correlated with supra-
additive effects on apoptosis at a 1:25 combination ratio. This ratio falls
within the 1:6 to 1:25 range associated with cytotoxic synergy, suggest-
ing a link between cell death and the induction of apoptotic mecha-
nisms by these drugs (Figure 4). Taken together, our data show that
FPD synergizes with SFN at specific combination ratios to induce cell
death in EGFR/HER-2 and mutant RAS/RAF BC model systems. We
hypothesize that the ability of FPD to synergize with SFN in these
models may be associated with dependency on constitutively elevated
EGFR/HER2 and Ras-MAPK activity. Interestingly, FPD has previ-
ously been shown to synergize with trastuzumab in inducing cyto-
toxicity in HER-2 BC lines through apoptotic mechanisms that
involved suppression of EGFR expression [34]. In line with our obser-
vations, synergy between FPD and trastuzumab was not observed in
hormone-dependent cells [34]. FPD has also been shown to promote
lethality of the dual EGFR/HER-2 inhibitor lapatinib in a greater than
additive manner [35]. The latter studies support our observations and,
together, highlight the importance of co-targeting strategies centered
on inhibiting Ras-MAPK and CDK signaling concurrently.
Significant toxicity issues in phase I FPD trials have been observed
with maximal tolerable doses (MTDs) of FPD including leukopenia,
nausea, vomiting, diarrhea, hypotension, and pro-inflammatory syndrome
[36]. In this study, animal cohorts were treatedwith sub-MTDs of FPD,
SFN, or FPD-SFN. In addition, Cremophor EL, a polyethoxylated
castor oil commonly used to improve water solubility of SFN and
other drugs, was used at levels below reported toxicity thresholds in
mice [29,37]. Importantly, adverse toxicity issues such as lethality or
severe weight loss were not observed in any of the individual cohorts
over the course of the treatment period (vehicle, 22.8 ± 0.09 g; SFN,
25.5 ± 0.04 g; FPD, 24.6 ± 0.08 g; SFN + FPD, 26.7 ± 0.06 g; mean ±
SD). At these nontoxic sub-MTDs, FPD potentiated the antitumor
effects of SFN in a mammary xenograft tumor model highlighting its
potential use at low-toxicity doses in FPD-SFN combination modalities
Figure 5. Inhibition of Ras-MAPK and Rb-E2F signaling by SFN-FPD combinations. MDA-MB-231 (A–C) and MDA-MB-468 (D–F) cells
were treated with SFN (5 μM; A, D), FPD (0.2 μM; B, E), or a 1:25 combination ratio of FPD-SFN (0.2 μMand 5 μM, respectively; C, F). Erk phos-
phorylation at T202/Y204 indicative of its active state. Rb phosphorylation at S807/811 indicative of inactivation catalyzed by CDKs [33]. Loading
was assessed by levels of the Ras GTPase-activating protein, RasGAP. Blots are representative of two to three independent experiments.
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[30,38,39]. Cytotoxic potentiation by FPD, however, was associated
with FPD-SFN ratios ranging from 1:6 to 1:25 in cell lines. This would
limit the maximal SFN concentration in such combinations to about
5 μM that is 25-fold more than FPD (0.2 μM) and is below the EC50 of
SFN. At sub-EC50 SFN concentrations, the maximal kill efficacy (K Eff )
of the cocktail is in the order of 50% to 60% (Figure 2A). This suggests
that reduced systemic toxicity associated with the use of synergistic sub-
MTDFPD–sub-EC50 SFN ratios come at the expense of a 40% to 50%
reduction in K Eff. Assuming these ratios are also synergistic at higher
FPD concentrations (i.e., 0.8 μM), the maximal SFN concentration
allowed at a 1:25 ratio would be 20 μM. At this concentration, the K Eff
of the cocktail would be approximately 90%, which is 15% greater than
the K Eff of SFN alone. Under this assumption, synergy (and its asso-
ciated benefit of reduced systemic toxicity) would not come at the
expense of a loss in K Eff. Importantly, we used a 1:10 FPD/SFN dosing
ratio in mice that falls within ratio boundaries for cytotoxic potentiation
determined in cell lines (1:6-1:25). Thus, drug ratio effects observed
in vitromay correlate with effects in vivo, supporting the use of cell-based
drug ratio studies for guiding initial dosing experiments in preclinical
mouse models. However, it remains unclear what the true impact of
changes in FPD/SFN ratios and/or doses would be on systemic toxicity
and tumor response in the clinic. It also remains unclear whether poten-
tial reductions in toxicity associated with FPD-SFN combinations come
at the expense of an overall loss in tumor response. The latter questions,
including possible trade-offs between toxicity and tumor response, still
remain to be addressed in the clinic.
Erk inhibition by SFN inMDA-MB-231 cells correlated with reduc-
tions inMcl-1 expression levels and suppression of pRb, suggesting that
Mcl-1 and Rb are regulated byMek-Erk–dependent signaling. Reduced
Mcl-1 expression and Rb phosphorylation have been previously cor-
related with antiapoptotic and proliferative effects associated with inhib-
ition of the Ras-MAPK pathway [40]. For example, Mcl-1 induction
downstream of the Ras-MAPK signaling has been shown to promote
BC cell survival [41]. In addition, phosphorylation-dependent inactivation
of Rb through cyclin D1 induction downstream of the Ras-MAPK
pathway was shown to lock cells in G1 and induce apoptosis [14,24].
Our results therefore are consistent with a model in which Mek-Erk–
dependent Raf signal suppression by SFN inhibits downstream Mcl-1
and pRb-dependent survival signaling in MDA-MB-231 cells (Fig-
ure 5). SFN also inhibited Mcl-1 levels in MDA-MB-468 cells but
paradoxically increased Erk and Rb signaling. Failure to suppress Erk
signaling suggested that Mek-Erk–independent Raf signaling mecha-
nismsmay contribute to survival in this line, possibly through inhibition
of direct Rb-Raf interactions or Rb phosphorylation by Raf [13,42].
Consistent with this, SFN has previously been shown to promote
apoptosis with Mcl-1 suppression through Mek-Erk–independent
mechanisms [11,43–45]. However, the mechanistic basis for the para-
doxical increases in pErk and pRb in these cells is unclear. SFN has been
shown to dose-dependently activate CRAF through BRAF-CRAF
dimerization [46,47]. SFNwas also shown to induce CRAF (and down-
stream Erk activation) in epithelial cells isolated from polycystic livers
through a protein kinase A–dependent BRAF-CRAF dimerization
mechanism [47]. It is hence plausible that in MDA-MB-468 cells,
SFN induces CRAF activation through BRAF heterodimerization lead-
ing to enhanced pErk and pRb signaling through Mek-Erk–dependent
and –independent pathways, respectively.
FPD, which has been shown to induce apoptosis through Mcl-1
[35,48], enhanced the extent to which Mcl-1 levels were suppressed
by SFN in both MDA-MB-231 and MDA-MB-468 cells. FPD also
enhanced the durability of suppression of Rb phosphorylation by
SFN in MDA-MB-231 cells. The failure of FPD to inhibit Erk sug-
gests that the latter FPD effects are Mek-Erk independent, likely
involving direct inhibition of CDKs. Thus, FPD-SFN–potentiating
effects on pRb suppression and reduction of Mcl-1 expression cor-
relate with cytotoxic synergy exhibited by this combination at the
cellular level. We speculate that concomitant suppression of Mek-
Erk–dependent and –independent pathways could underlie cytotoxic
synergy exhibited by SFN-FPD combinations. Similar molecular
mechanisms may also operate in vivo, where the enhanced antitumor
growth effects and reduced pulmonary metastatic burden of this
combination correlated with maximal repression of pErk, pRb, and
Mcl-1 expression (Figures 6 and 7). These observations are not with-
out precedent. Lapatinib and CDK inhibitors (including FPD) syner-
gized to kill BC cells in vivo and in vitro, and this correlated with
inhibition of Mcl-1 expression [35]. In addition, trastuzumab and
FPD synergistically inhibited proliferation of HER-2–overexpressing
SKBR3 and BT474 cells and inhibited Erk signaling, cyclin D1 expres-
sion, and Rb phosphorylation more potently in combination [28].
Importantly, we cannot exclude the involvement of the antiangiogenic
properties that have been associated with both SFN and FPD. SFN has
been shown to directly target the RTK activity of vascular endothelial
Figure 6. Combined treatment of SFN and FPD results in enhanced
tumor suppression in vivo. (A) Tumor development profiles of drug-
treated cohorts (sixmice/cohort). Estimates ofmean tumor volume±
SEM are shown. Control versus SFN, FPD, or SFN-FPD (P < .0001;
two-way analysis of variance). SFN-FPD versus SFN or FPD (P <
.0001; two-way analysis of variance). (B) Pulmonary metastatic
tumor burden assessed by quantification of the ratio (±SEM) of
human Cep17 signal and DAPI-stained nuclei in each cohort (n =
24; see also Figure W2). Significant P values (t test) are indicated.
948 Sorafenib-Flavopiridol in Breast Cancer Nagaria et al. Neoplasia Vol. 15, No. 8, 2013
growth factor receptors 1 to 3 and PDGFR-β, while FPD has been
shown to downregulate vascular endothelial growth factor receptor
mRNA and protein levels induced by hypoxia [17,49,50]. Consistent
with these observations, we have observed that FPD- and SFN-treated
tumors exhibit reduced expression of the angiogenic marker CD31
(PECAM-1). More strikingly, combined FPD and SFN treatment cor-
related with lower CD31 expression levels than that observed in the
presence of either drug alone (Figure W4). Taken together, these data
suggest that cooperative inhibition of angiogenesis by FPD and SFN
may also contribute to cytotoxic synergy exhibited by this combination.
SFN alone did not inhibit Erk activity in tumors, although
marked inhibition was observed in MDA-MB-231 cells in vitro. This
is in agreement with a number of studies showing that inhibition of
tumor growth by SFN is not always associated with Erk inhibition
[51]. For example, SFN inhibited tumor growth in renal and colo-
rectal tumor models but failed to inhibit Erk activity [17,50]. Unaf-
fected pErk levels in response to SFN could reflect failure to detect
Erk inhibition due to inappropriate sampling time or to failure to
achieve sufficient inhibitor levels in microenvironmental and cell
compartments. Alternatively, Erk-independent antitumor effects
may be attributable to SFN’s antiangiogenic function [51] or to
Mek-Erk–independent antiproliferative/apoptotic Rb signaling
[13,52]; this is supported by reduced pRb levels in SFN-treated
MDA-MB-231 cells and tumors (Figure 7C ). Lastly, FPD (and
SFN) alone suppressed Mcl-1 expression in MDA-MB-231 cells
but failed to inhibit its expression in tumors. We propose that similar
effects as those proposed for pErk apply to failed Mcl-1 suppression
in tumors; these include pharmacodynamic factors, as well as the
antiangiogenic function ascribed to FPD.
In summary, our data show that FPD-SFN combinations exhibit
cytotoxic synergy in EGFR/HER-2 and mutant RAS/RAF BC model
systems. This correlates with enhanced tumor growth inhibition at
the orthotopic site and with reduced pulmonary metastatic burden.
These preclinical data support possible antitumor applications of
FPD-SFNmodalities in adjuvant and advanced settings of BC therapy.
The potential therapeutic benefits of adding FPD to current SFN treat-
ment modalities in BC are suggested by recent successes of SFN in BC
trials. SFN has been shown to prolong progression-free survival of
advanced or metastatic HER-2–negative BC patients previously treated
with anthracyclines and/or taxanes (SOLTI-0701; [12]). SFN has also
been shown to increase survival of HER-2–negative patients with dis-
ease progression during or after bevacizumab therapy [53]. Trastuzumab
is currently the main targeted treatment for HER-2–positive cases and
lapatinib for advanced/metastatic cases. We have observed that FPD-
SFN combinations exhibit synergy in the HER-2–overexpressing cell
line SKBR3, supporting the use of SFN as a potential alternative to
trastuzumab and lapatinib in combination with FPD (discussed above).
In this context, SFN may provide potential improvements in thera-
peutic efficacy over HER-2 inhibitors because it directly targets RAF,
a central regulatory nexus in RTK-mediated proliferative and survival
signaling. Unlike HER-2 inhibitors, SFN provides the added benefit
of enhancing FPD-associated antiangiogenic effects (Figure W4). Alter-
natively, FPD-SFN combination therapy could also be employed as
antiresistance strategies in cases refractory to trastuzumab or lapatinib.
Lastly, TN BC, the most aggressive BC subtype, is characterized by a
lack of estrogen, progesterone, and HER-2 receptor expression and
with EGFR overexpression [7,54]. The observed synergy in EGFR–
overexpressing MDA-MB-468 and in TN MDA-MB-231 cell/tumor
models supports the use of this combination inTNBC.Thus, FPD-SFN
combinationmodalities may be suitable for treatingHER-2–positive BC,
as well as aggressive HER-2–negative BCs exhibiting EGFR or TN
molecular signatures.
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Figure 7. SFN and FPD cooperatively inhibit Erk, Mcl-1, and Rb signaling in tumors. (A) Immunoblots of lysates prepared from resected
tumors assessing pErk, pRb, andMcl-1 levels in the indicated cohorts (n= 24). Loading was assessed by tubulin levels. (B–D) Densitometry
analyses of the average intensity of pErk, pRb, and Mcl-1. The mean ± SEM intensity expressed as a ratio of tubulin intensity across treat-
ment cohorts (six mice/cohort) is shown. Significant P values (t test) are indicated. A.U., arbitrary units.
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Figure W1. Pathologic assessment of pulmonary metastatic tumor load in treatment cohorts. Histology of tumor-bearing mouse lungs
after 15 doses of (A) SFN and FPD, (B) SFN, (C) FPD, and (D) vehicle control (PBS), compared with (E) normal lung. Hematoxylin and
eosin (HE)–stained lung sections (×4) showed poorly differentiated carcinoma in both treatment and control groups relative to normal
lung. Tumor burden tended to vary between groups, but the pattern of metastasis was diffuse and bilateral in all cases with readily
apparent vascular involvement, suggesting a hematogenous route of spread. The morphology of these metastatic lesions resembled
that of tumors at the orthotopic engraftment site (see Figure W3), and FISH analysis using a human-specific Cep17 probe confirmed the
neoplastic cells in the lung to be human in origin. (A, B) Isolated nests (arrows) or irregular nodular-like (dashed arrows) distributions of
neoplasms with substantial preservation of normal lung histology were evident in the combination and SFN-treated groups (compare with
Figure W1E ). (C, D) Confluent sheets of neoplastic cells (asterisks) with diffuse involvement of pleura and obliteration of a significant
portion of alveolar airspace were apparent in FPD-treated and control cohorts (compare with A and B). (E) Normal BalbC-RAG2−/−|
IL2Rγc−/− mouse lung showing variably sized alveolar airspaces separated by delicate paucicellular interstitial parenchyma and
surrounded by a thin visceral pleura. Corresponding locations of each FFPE section are shown in the right upper inserts.
Figure W2. Quantification of pulmonary metastatic tumor load by FISH. Whole lungs were resected from each mouse 35 days post-
engraftment and prepared in FFPE tissue blocks (n= 24). Five-micrometer sections from each mouse were prepared for species-specific
FISH-based detection of metastasized MDA-MB-231 using a Cep17 SpectrumGreen (SpG) probe and counterstained with DAPI to detect
nuclei. Adjacent tissue sections were stained with HE for corresponding pathologic assessment. Representative HE and FISH/DAPI stains
of regions in Figure W1, A–D. (A–E) SFN-FPD combination cohort. (F–J) SFN cohort. (K–O) FPD cohort. (P–T) Control cohort. Lungs with
the least metastatic burden (A–E) show tumors restricted to the interstitium with preservation of alveolar and vascular architecture, while
in the more severely affected lungs (K–O and P–T) tumors have destroyed native parenchymal architecture that completely fill the air-
spaces. Lungs with amoderate burden of metastasis (F–J) show expansion of the interstitium and destruction of capillaries by tumors, yet
alveolar airspaces are maintained.
Figure W4. Enhanced reduction of CD31 (PECAM-1) expression in tumors isolated from the FPD-SFN–treated cohort. (A) Immunoblots of
lysates prepared from resected tumors assessing CD31 expression levels in the indicated cohorts (n = 24). Loading was assessed by
tubulin levels. (B) Densitometry analyses of the average intensity of CD31 staining. The mean ± SEM intensity expressed as a ratio of
tubulin intensity across treatment cohorts (six mice/cohort) is shown. Significant P values (t test) are indicated. A.U., arbitrary units.
Figure W3. Histology of FFPE primary orthotopic MDA-MB-231 xenograft tumors; ×20 (A) and ×40 (B) magnifications of HE-stained
FFPE lung sections are shown. Native glandular breast tissue is completely replaced by a high-grade breast carcinoma characterized by
a solid growth pattern (arrows), significant nuclear pleomorphism, and numerous mitotic figures (dashed arrows). The tumor extensively
infiltrates mammary adipose tissue, and there is abundant central tumor-type necrosis (asterisk). Corresponding location of each FFPE sec-
tion is shown in the right upper inserts.
